NCT01999101已完成2 期
A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NAFLD patients
- •Weight > 65 kg
- •BMI > 25 and < 40
- •Negative blood or urine pregnancy test (for females of childbearing potential) collected at screening followed by another negative serum pregnancy test collected within 24 hours prior to the first dose of study drug.
- •Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least two effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least two effective methods of contraception with all sexual partners unless they have had a prior vasectomy
- •Must be willing and able to give written informed consent and agree to comply with the study protocol.
- •Sinus rhythm in 12-lead ECG
排除标准
- •Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use) within 1 year of first dose.
- •History or other evidence of a medical condition associated with chronic liver disease other than.
- •History or other evidence of decompensated liver disease (Child-Pugh Grade B or higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions consistent with decompensated liver disease.
- •Concomitant intake of fibrates or statins (at least 4-6 weeks before start; considering half life of medication).
- •Any clinically relevant findings in ECG (identified via 24h-Holter ECG or 12-Lead ECG) at screening
- •History of any structural cardiac disease.
- •In addition, patients with documented or presumed unstable coronary artery disease, stable or unstable cardiovascular disease or cerebrovascular disease.
- •One or more of the following conditions: (1) poorly controlled hypertension, OR (2) screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.
- •Type I or II diabetes with HbA1C > 6.5% at screening and/or fasting plasma glucose > 7mmol/L (> 126 mg/dl).
- •History or other evidence of a clinically relevant ophthalmologic disorder due to diabetes mellitus or hypertension or history or other evidence of severe retinopathy (e.g., cytomegalovirus, macular degeneration).
- •Known sensibility to any ingredients contained in the investigational medicinal product (IMP)
- •All conditions that do not allow magentic resonance (MR) assessments
- •History of having received any investigational drug ≤ 3 months and/or 6 x half-life prior to the first dose of study drug or the expectation that such drugs will be used during the study. Patients enrolled in this study cannot be enrolled in another study for either research, diagnostic or treatment purposes.
- •Woman with childbearing potential unless using adequate contraception (see inclusion criteria); females who are pregnant or breast feeding.
- •History of severe allergic
- •Evidence of an active or suspected cancer, or a history of malignancy within the last 2 years, with the exception of patients with basal cell carcinoma that has been excised and cured.
- •History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- •History of bleeding disorders or anticoagulant use
- •History or other evidence of chronic pulmonary disease associated with functional limitation.
- •History of uncontrolled severe seizure disorder.
- •Poorly controlled thyroid dysfunction.
- •History of major organ transplantation with an existing functional graft.
- •Any signs of acute infection or inflammation
- •History or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
- •Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins, proflavins, curcumin. (at least 4-6 months before the study)
- •Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM), Hebatitis B surface antigen (HBsAg), Anti-Hepatits B core Antigen Immunglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab.
- •Subjects who have undergone surgery within the last 3 months.
- •Subjects who have had a prior gastrointestinal surgery.
- •Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to b unsuitable by the investigator for any other reason
- •Imprisonment
研究组 & 干预措施
Px-104
Experimental
Px-104 capsules, 5 mg
干预措施: Px-104 (Drug)
结局指标
主要结局
Safety
时间窗: 28 days
Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days. Change day 28 vs. day 1
次要结局
- Change of hepatocellular lipid content(day 1 and day 28)
- Changes in oral glucose tolerance test (oGTT)(baseline and day 27)
- Change from baseline in fibroblast growth factor 19 (FGF-19)(days 1, 7, 14, 21 and 28)
- Change from baseline in plasma bile acid concentration(days 1, 7, 14, 21, and 28.)
- Pharmacokinetics of Px-104 and conjugates(day 1 and day 28)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Safety Study of Px-104 in Patients with liver diseaseon-alcoholic fatty liver disease (NAFLD)MedDRA version: 16.1Level: PTClassification code 10024670Term: Liver disorderSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2013-002984-24-ATPhenex Pharmaceuticals AG
已完成
1 期
Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT StudyKidney TransplantationNCT04837092Nantes University Hospital10
已完成
1 期
Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429HealthyNCT01117233Pfizer40
已完成
1 期
Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy AdultsTuberculosisNCT00871949Sequella, Inc.19
已完成
1 期
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy VolunteersSchizophreniaNCT01511510Biogen39